ARID1B mutation	Non Small Cell Lung Cancer	ARID1B mutation	Non Small Cell Lung Cancer	Immunotherapy Sensitive: B - Late Trials Immunotherapy Sensitive : B	Immunotherapy Sensitive: B - Late Trials Immunotherapy Sensitive : B
ARID1B mutation + TMB-H	Non Small Cell Lung Cancer	ARID1B mutation + TMB-H	Non Small Cell Lung Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
ARID1B mutation	Follicular Lymphoma	ARID1B mutation	Follicular Lymphoma	R-CHOP Resistant: C3 – Early Trials R-CHOP Resistant : C3	R-CHOP Resistant: C3 – Early Trials R-CHOP Resistant : C3
ARID1B mutation	Gastrointestinal Cancer	ARID1B mutation	Gastrointestinal Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
ARID1B deletion	Mantle Cell Lymphoma	ARID1B deletion	Mantle Cell Lymphoma	temsirolimus Resistant: C3 – Early Trials temsirolimus Resistant : C3	temsirolimus Resistant: C3 – Early Trials temsirolimus Resistant : C3
ARID1B mutation	Solid Tumor	ARID1B mutation	Solid Tumor	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3
ARID1B overexpression	Diffuse Large B Cell Lymphoma	ARID1B overexpression	Diffuse Large B Cell Lymphoma	R-CHOP Resistant: C3 – Early Trials R-CHOP Resistant : C3	R-CHOP Resistant: C3 – Early Trials R-CHOP Resistant : C3

ARID1B (AT-Rich Interaction Domain 1B)

Associations(7)

Associations
(7)